BioSpace News Archive

Business

Fusion Pharmaceuticals and Niowave Announce Actinium-225 Collaboration and Supply Agreement

Fusion to invest $5M for guaranteed access to actinium-225 supply Agreement augments Fusion’s existing supply as company expands pipeline of actinium-based radio pharmaceuticals.

June 10, 2022
·
6 min read
Drug Development

ORYZON at EHA-2022: Iadademstat 42-month ALICE Data Demonstrate Robust Efficacy in Combination with Azacitidine in AML

Oryzon Genomics, S.A. today presents new positive efficacy data from its ongoing Phase IIa ALICE trial, investigating iadademstat in combination with azacitidine in elderly or unfit patients with acute myeloid leukemia (AML).

June 10, 2022
·
7 min read
Genetown

Vor Bio Successfully Demonstrates Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment Presented at EHA

Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced successful first of its kind dual editing of CD33 and CLL-1 in human hematopoietic stem cells (HSCs) demonstrating continued progress on its novel approach for the treatment of acute myeloid leukemia (AML).

June 10, 2022
·
4 min read
Mindset Pharma Receives Notice of Allowance for Patent Application Covering Psilocin Derivatives for the Treatment of Central Nervous System Disorders

Mindset Pharma Inc. today announced that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance for Mindset’s patent application number 17/387,845.

June 10, 2022
·
3 min read
Drug Development

Vincerx Pharma Presents Preclinical and Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Lymphoma at the European Hematology Association 2022 Congress

Vincerx Pharma, Inc. today announced a poster presentation of preclinical and clinical data on VIP152, the Company’s PTEFb/CDK9 inhibitor, at the European Hematology Association (EHA) 2022 Congress, being held virtually and in Vienna, Austria from June 9-12, 2022.

June 10, 2022
·
9 min read
Drug Development

Janssen Presents Updated Results Evaluating First-in-Class GPRC5D Bispecific Antibody Talquetamab in Heavily Pretreated Patients with Multiple Myeloma

The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated results from the Phase 1 MonumenTAL-1 first-in-human dose-escalation study of talquetamab (NCT03399799).

June 10, 2022
·
21 min read
Chung-Ang University Researchers Use Biomolecule-Loaded Metal-Organic Frameworks Nanopatterns to Aid Artificial Stem Cell Differentiation

Stem cells give rise to all other cells and tissues with specialized functions, through a process called “differentiation,” in which stem cells divide to form daughter cells.

June 10, 2022
·
3 min read
Biotech Bay

Jaguar Health to Participate in BIO International Convention (BIO 2022)

Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Karen Brunke, PhD, the company’s Executive Vice President of Corporate and Business Development, will be attending BIO 2022, taking place at the San Diego Convention Center from June 13 - 16, 2022.

June 10, 2022
·
6 min read
Genetown

T2 Biosystems Receives Nasdaq Extension to Comply with Bid Price Rule; Company to Transfer to Nasdaq Capital Market

T2 Biosystems, Inc. announced that the Nasdaq Hearings Panel has granted the Company’s request for an extension until November 1, 2022, to regain compliance with Nasdaq’s minimum bid price requirement, as set forth in Nasdaq Listing Rule 5550.

June 10, 2022
·
4 min read
Biotech Beach

Neoss® Group releases the NeoScan™ 1000 to mark 20 years of Intelligent Simplicity.

As part of Neoss’ milestone celebration delegates at the Neoss Integrate 2022 congress in Gothenburg, Sweden were given the first access to the NeoScan 1000 intraoral scanner which is set for full commercial launch in September 2022.

June 10, 2022
·
1 min read